Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metered dose inhalers: current and future uses

M L Levy

    British Journal of Clinical Practice. Supplement
    |May 1, 1997
    PubMed
    Summary
    This summary is machine-generated.

    Pressurised metered dose inhalers (pMDIs) are a cost-effective choice for respiratory drug delivery. Their use is expected to grow for asthma and COPD treatment, with potential for novel therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria.

    The British journal of dermatology·2021
    Same author

    Consensus, collaboration and care coordination.

    The British journal of dermatology·2019
    Same author

    Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.

    Oncogene·2014
    Same author

    Unrecognized visual field deficits in children with primary central nervous system brain tumors.

    Journal of neuro-oncology·2011
    Same author

    The GINA Asthma Challenge: reducing asthma hospitalisations.

    The European respiratory journal·2011
    Same author

    Properties of the COPD assessment test in a cross-sectional European study.

    The European respiratory journal·2011
    Same journal

    Treatment of dyslipidaemias with fluvastatin.

    British journal of clinical practice. Supplement·2009
    Same journal

    Lipoprotein(a) as a marker for coronary heart disease.

    British journal of clinical practice. Supplement·2009
    Same journal

    Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial.

    British journal of clinical practice. Supplement·2009
    Same journal

    Risk factor management: the cardiologist's perspective.

    British journal of clinical practice. Supplement·2009
    Same journal

    Fluvastatin in combination with other lipid-lowering agents.

    British journal of clinical practice. Supplement·2009
    Same journal

    The patient at risk: who should we be treating?

    British journal of clinical practice. Supplement·2009
    See all related articles

    Area of Science:

    • Respiratory medicine
    • Pharmacology
    • Medical devices

    Background:

    • Respiratory diseases like asthma and COPD represent a significant global health and economic burden.
    • Inhaled drug delivery is the preferred method for treating respiratory conditions.
    • Current inhaled delivery systems include pMDIs, dry powder devices, pMDIs with spacers, and nebulizers.

    Purpose of the Study:

    • To review the role and future prospects of pressurised metered dose inhalers (pMDIs) in respiratory medicine.
    • To discuss the impact of environmental regulations on pMDI propellant development.
    • To project the increasing demand for pMDIs in managing asthma and COPD.

    Main Methods:

    • Review of current literature on inhaled respiratory drug delivery systems.

    Related Experiment Videos

  • Analysis of market data and trends for pMDIs in the UK.
  • Examination of factors influencing the adoption of pMDIs for various respiratory conditions.

    • Main Results:

    • pMDIs are the most economical inhaled delivery system available in the UK.
    • The development of alternative propellants for pMDIs is ongoing due to international agreements to phase out CFCs.
    • The use of pMDIs is projected to increase, driven by clinical guidelines and expanding applications.

    Conclusions:

    • pMDIs are a vital and cost-effective tool for respiratory drug delivery.
    • Future innovations in drug delivery, including gene therapy, may leverage pMDI technology.
    • The expanding role of pMDIs is anticipated to improve patient outcomes for asthma and COPD.